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2013;57:35S-43S.EDITORS’ COMMENTARYThomas L. Forbes, MD, and Jean-Baptiste Ricco, MD, PhD, London, Ontario, Canada; and Poitiers, FranceThoracic endovascular repair (TEVAR) has not yet demon-
strated superiority over medical treatment for patients with
uncomplicated type B aortic dissection.1 In this clinical setting,
rupture is uncommon except in cases with a large aneurysm at
the entry site or large false lumen dilatation. However, aortic
branch occlusion by the propagation of the false lumen and subse-
quent malperfusion syndrome may complicate the initial presenta-
tion. Until now, a complication-speciﬁc approach has been
adopted as the standard of care, but endovascular treatment
(TEVAR) sealing the aortic tear and achieving depressurization
of the false lumen has the potential to reduce both early and late
complications and to change treatment strategies. However, as
explained by our debaters, many questions remain and it is not
clear if we need more evidence before accepting TEVAR as routine
in these patients with uncomplicated type B aortic dissection.
UNCOMPLICATED ACUTE TYPE B AORTIC
DISSECTION
Meta-analysis2 of three studies comparing medical therapy and
TEVAR for acute uncomplicated type B aortic dissection3-5 found
a lower early mortality rate with medical therapy compared with
TEVAR (odds ratio, 0.50; 95% conﬁdence interval, 0.27-0.95).
In three other studies comparing TEVAR and open surgery,5-7
the pooled early mortality rate was signiﬁcantly higher for open
surgery (odds ratio, 2.66; 95% conﬁdence interval, 1.37-5.17).
However, in these nonrandomized studies, comparison of medical
therapy vs TEVAR or vs open surgery for acute uncomplicated
type B aortic dissection is often biased with an overestimation of
low complication rates in patients at lower risk and usually assigned
to medical therapy. Nevertheless, according to these data, there is
evidence, although not from level 1 studies, that patients with
uncomplicated acute type B aortic dissection do well with medical
treatment alone.2 This strategy was debated by Jan Brunkwall who
supports the use of TEVAR in acute type B aortic dissection
following data from the Acute Dissection: Stent Graft or Best
Medical Therapy (ADSORB) study8 showing that TEVAR allows
true lumen expansion. However, in this trial, low recruitment
resulted in an underpowered study not being able to demonstrate
a potential difference in mortality between the two groups.
UNCOMPLICATED CHRONIC TYPE B AORTIC
DISSECTION
Regarding chronic type B aortic dissection, the Investigation of
Stent Grafts in Patients with Type B Aortic Dissection (INSTEAD)
randomized controlled trial (RCT)9 showed that medical therapy
with close surveillance was associated with excellent all-cause and
aorta-related survival rates that were not improved by TEVAR. In
detail, the survival rate at 2 years was 88.9% 6 3.7% with TEVAR
vs 95.6% 6 2.5% with medical treatment (P ¼ .18). Similarly, the
aorta-related 2-year survival was comparable among the two
groups. As discussed by our debaters, with 11 deaths, the 2-year
death rate did not meet the assumption of 28 events for statisticalpower. Finally, the cluster end point of aorta-related death, cross-
over/conversion, and ancillary procedures was not statistically
different between the two groups with freedom from event in
72.5% 6 5.5% of the patients with medical treatment vs 77.2% 6
5.0% for TEVAR (P ¼ .65). It should be emphasized that in this
RCT, most patients were randomized 2 weeks after the onset of
symptoms; thus, those with early complications, who would most
likely beneﬁt from TEVAR, were not included in the study cohort.
In addition, among the seven patients who died in the TEVAR
group, four of themwithmalperfusion or impending rupture should
have been excluded from this RCT aimed at electivemanagement of
uncomplicated chronic type B aortic dissection.10 Despite these
criticisms, INSTEAD, the only RCT for chronic type B aortic
dissection supports a complication-speciﬁc approach instead of the
routine use of TEVAR. However, some encouraging data were
also reported in this trial showing aortic remodeling at 2 years
with true lumen recovery and false lumen thrombosis in 91.3% of
patients receiving TEVAR vs 19.4% of patients in the medical
group. This was not the end point of the study, but aortic remodel-
ing may be considered a surrogate for prevention of late aneurysm
formation.11
After an extensive review of the literature, our debaters
proposed different strategies and we suggest that medical manage-
ment with close imaging follow-up is probably the best strategy for
uncomplicated type B aortic dissection. However, as demonstrated
by our debaters, the evidence favoring this strategy is thin. Consid-
ering the lack of power of the ADSORB and INSTEAD trials, we
need large studies on type B aortic dissection stratiﬁed by type and
timing with long-term follow-up to provide optimal treatment
guidelines.
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